Navigation Links
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Date:2/11/2008

re reported.

Results of the pixantrone phase III clinical trial in aggressive, relapsed non-Hodgkin's lymphoma (NHL), known as the EXTEND or PIX301 trial, are expected in the summer of 2008. Depending on the results of this trial, CTI may begin a rolling New Drug Application (NDA) submission for pixantrone in the second half of the year. CTI has closed enrollment on its other clinical trials of pixantrone, including the RAPID trial, a first-line randomized phase II study of CHOP-R versus CPOP-R in previously untreated aggressive NHL patients, and the PIX303 trial, a study of fludarabine, pixantrone and rituximab (FP-R) compared to the combination of fludarabine and rituximab (F-R) in the treatment of patients who have received at least one prior treatment for indolent NHL.

"Based on feedback from both our partner Novartis and from a panel of oncology experts, all agreed the best step for the Company is to focus resources on obtaining XYOTAX and pixantrone approval with existing or completing phase III trials before making additional substantial investments in alternative indications for these products. Combined with reductions in phase III clinical trials costs for XYOTAX and pixantrone, we are projecting net cash operating expenses of $77 million in 2008," Bianco added.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most seri
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
2. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
3. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
4. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
5. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
6. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
7. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
8. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
9. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
10. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... July 11, 2014  Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... CLEVELAND, June 22, 2011 Clinical Research Management, ... in basic and applied research, clinical trials, and ... a new, 5-year, $97MM research support contract titled ... (SMMRS) to be performed at the Walter Reed ...
... June 22, 2011 ,   ... a novel platform technology for the oral delivery of ... Berelowitz, M.D., has been appointed the Chairman of its,Scientific ... Board of Directors in May 2010,and will now expand ...
... Biodesign, a drug discovery company that utilizes ultra-high throughput ... therapeutic agents against its novel disease-based targets, or its ... medicinal chemistry space at 8 Black Forest Road in ... 11,000 square feet of state-of-the-art research laboratories and office ...
Cached Biology Technology:ClinicalRM (formerly CRM) Awarded $97MM U.S. Army Contract to Support Military Clinical Research for the Warfighter 2Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board 2Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board 3VENENUM Biodesign Announces Opening of Medicinal Chemistry Labs 2
(Date:7/10/2014)... 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... Gino Pereira was interviewed on July 1 st ... Florida . Mr. Pereira discusses the company,s next generation ... and how the Wocket™ aims to replace a traditional wallet ... Cedric Harris tells Gino he has never heard of ...
(Date:7/10/2014)... DUBLIN , July 3, 2014 ... the addition of the "Global Gesture Recognition ... Market - Forecasts to 2020" report to ... Global Gesture Recognition & Touch-Less Sensing ... been around for a while, but the companies ...
(Date:7/10/2014)... According to a new market ... Systems Market Global Forecast, Market Share, Size, Growth and ... Control systems market was valued at USD 15,406.1 million ... CAGR of 12.6% from 2014 to 2019, to reach ... Browse the full Electronic Access Control Systems ...
Breaking Biology News(10 mins):Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5
... researchers led by Shawn P. McElmurry, Ph.D., P.E., assistant ... University,s College of Engineering, has confirmed that seasonal fluctuations ... areas throughout the United States and elsewhere in the ... with lead. The study, published in the ...
... Mitchell, MD, a professor of public health (epidemiology) and ... Public Health and Medicine, recently received the Godfrey P. ... National Birth Defects Prevention Network. Mitchell, who is also ... was recognized for his significant lifetime contributions to the ...
... Registration is now open for the Joint Annual Meeting of ... Animal Science. The meeting will take place in Indianapolis, IN ... Meeting (JAM) will feature 35 symposia on topics such as ... planned additional high-level workshops, including a hands-on media training workshop ...
Cached Biology News:BU researcher receives highest honor from the National Birth Defects Prevention Network 2
... Cleland’s Reagent, Immobilized White solid. ... form of DTT on polyacrylamide resin with applications ... 233153 , 233156 , and ... no soluble components are added to the system. ...
... HVJ (hemagglutinating virus of Japan, also named ... tool for transfection of molecules by means ... for siRNA (RNAi), Protein, Oligo, cDNA, Antibodies, ... in vivo. GenomONE-Neo EX has a high ...
... White solid.. PACKAGED UNDER INERT GAS. Cyclizes as ... "driven" to completion. A protective agent for SH ... many other preparations. Blocks the lethal and hypnotic ... Contaminants: Heavy metals: ≤1 ppm. ...
... sequencing of Salmonella genomes has allowed the ... PCR* primer pairs. The S. enterica Typhimurium ... chromosome (4,857,432 bp; 4,440 ORFs) and a ... ORFmers from Sigma-Genosys have been designed to ...
Biology Products: